Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers

Vaccine

Volumn 26, Issue 19, 2008, Pages 2344-2349

  Littmann, Martina ^a   Hülße, Christel ^a   Riffelmann, Marion ^b,c   Wirsing von König, Carl Heinz ^b,c  

^a Landesamt für Gesundheit und Soziales Mecklenburg Vorpommern State Office for Health and Social Affairs   (Germany)

^b Institut fuer Infektiologie Krefeld   (Germany)

^c HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

Acellular vaccine; Antibodies; Health care workers; Pertussis

Indexed keywords

ANTIBODY; HEMAGGLUTININ; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PAC MERIEUX; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE PERSONNEL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LONG TERM CARE; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADHESINS, BACTERIAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL OUTER MEMBRANE PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GERMANY; HEALTH PERSONNEL; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MIDDLE AGED; PERTUSSIS TOXIN; PERTUSSIS VACCINE; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA;

EID: 42649133135     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.065     Document Type: Article

References (25)

1. Edwards K.M. Pertussis vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), WB Saunders, Philadelphia, PA 471-528
2. Wendelboe A.M., van Rie A., Salmaso S., and Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 24 (2005) S59-S61
3. Halperin S.A. The control of pertussis-2007 and beyond. N Engl J Med 356 (2007) 110-113
4. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut. Version January 2000: Epidem Bulletin 2000;2:9-20, Version July 2002: Epidem Bulletin 2002;28:227-42.
5. Calugar A., Ortega-Sanchez I.R., Tiwari T., Oakes L., Jahre J.A., and Murphy T.V. Nosocomial pertussis: cost of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 42 (2006) 981-988
6. Peadon E., and Cooper C. Whooping cough: are health-care workers putting children at risk?. J Paediatr Child Health 43 (2007) 398-402
7. Swidsinski S., Schlesinger F.L., and Mebel S. Keuchhusten: nicht augerottet aber vergessen. Z Ärztl Fortb (Jena) 83 (1989) 309-312
8. Safety data on PAC Mérieux.
9. Herden P., Bier N., Schneeweiss B., Palitsch D., and Wirsing von König C.H. Interchangeability of acellular pertussis vaccines during primary immunization. Pediatr Infect Dis J 19 (2000) 757-759
10. Wirsing von König C.H., Gounis D., Schmitt H.J., Laukamp S., and Bogaerts H. Single sample serological diagnosis of pertussis. Eur J Clin Microbiol Infect Dis 18 (1999) 341-345
11. Wirsing von König C.H., and Schmitt H.J. Epidemiological aspects and diagnostic criteria for a protective efficacy field trial of a pertussis vaccine. J Infect Dis 174 (1996) S281-S286
12. Knuf M., Zepp F., Meyer C., Grzegowski E., Wolter J., Riffelmann M., et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 24 (2006) 2043-2048
13. Lynn F., Reed G.F., and Meade B.D. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol 3 (1996) 689-700
14. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 190 (2004) 535-544
15. McIntyre P., Turnbull F.M., Egan A.M., Burgess M.A., Wolter J.M., and Schuerman L.M. High levels of antibody in adults three years after vaccination with a reduced content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 23 (2004) 380-385
16. Edelman K.J., He Q., Makinen J.P., Haanpera M.S., Tran Minh N.N., Schuerman L., et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 39 (2004) 179-185
17. Edelman K., He Q., Mäkinen J., Sahlberg A., Haanperä M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 44 (2007) 1271-1277
18. Pichichero M.E., Blatter M.M., Kennedy W.A., Hedrick J., Decamps D., and Friedland L.R. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 117 (2006) 1084-1093
19. Rothstein E.P., Anderson E.L., Decker M.D., Poland G.A., Reisinger K.S., Blatter M.M., et al. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Vaccine 17 (1999) 2999-3006
20. Christie C.D.C., Garisson K.M., Kiely L., Gupta R.K., Heubi J., and Marchant C.D. A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993. Clin Infect Dis 33 (2001) 997-1003
21. Pichichiero, Edwards K.M., Anderson E.L., Rennels M.B., Englund J.A., Yerg D.E., et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four-to-six-year-old children. Pediatrics 105 (2000) e11
22. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96 (1995) 548-557
23. Van der Wielen M., Van Damme P., Joossens E., Francois G., Meurice F., and Ramalho A. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 18 (2000) 2075-2082
24. Van Damme P., and Burgess M. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine 22 (2004) 305-308
25. Hallander H.O., Gustafsoson L., Ljungman M., and Storsaeter J. Pertussis antitoxin decay after vaccination with DTaP Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 23 (2005) 5359-5364